IRIS
SANTORO, Armando
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 47.751
AS - Asia 23.137
EU - Europa 8.606
SA - Sud America 4.591
AF - Africa 1.229
Continente sconosciuto - Info sul continente non disponibili 797
OC - Oceania 40
AN - Antartide 1
Totale 86.152
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 46.542
SG - Singapore 14.340
BR - Brasile 3.747
CN - Cina 3.433
IT - Italia 2.446
VN - Vietnam 2.367
FI - Finlandia 1.407
IE - Irlanda 1.131
NG - Nigeria 809
DE - Germania 741
HK - Hong Kong 736
CA - Canada 717
FR - Francia 674
GB - Regno Unito 545
IN - India 443
NL - Olanda 375
SE - Svezia 317
AR - Argentina 303
TR - Turchia 288
BD - Bangladesh 239
IQ - Iraq 194
RU - Federazione Russa 188
MX - Messico 187
IL - Israele 153
EC - Ecuador 147
ID - Indonesia 124
ZA - Sudafrica 118
CO - Colombia 117
JP - Giappone 115
PL - Polonia 105
UA - Ucraina 103
BE - Belgio 101
ES - Italia 95
PK - Pakistan 89
CL - Cile 81
MA - Marocco 79
UZ - Uzbekistan 66
VE - Venezuela 66
SA - Arabia Saudita 57
PY - Paraguay 55
CR - Costa Rica 53
MY - Malesia 51
PH - Filippine 50
JO - Giordania 40
AE - Emirati Arabi Uniti 38
EG - Egitto 38
GT - Guatemala 37
HN - Honduras 36
JM - Giamaica 36
TN - Tunisia 36
RO - Romania 35
AU - Australia 34
CZ - Repubblica Ceca 34
IR - Iran 34
LT - Lituania 34
DZ - Algeria 33
KE - Kenya 33
UY - Uruguay 33
AT - Austria 32
KR - Corea 32
NP - Nepal 32
CH - Svizzera 26
PE - Perù 26
DO - Repubblica Dominicana 25
KZ - Kazakistan 24
TH - Thailandia 24
OM - Oman 23
AZ - Azerbaigian 22
TT - Trinidad e Tobago 22
A2 - ???statistics.table.value.countryCode.A2??? 21
BG - Bulgaria 21
EU - Europa 21
NI - Nicaragua 21
HU - Ungheria 19
ET - Etiopia 18
PT - Portogallo 18
EE - Estonia 17
GR - Grecia 16
LB - Libano 16
PR - Porto Rico 16
SV - El Salvador 15
NO - Norvegia 14
SN - Senegal 14
BY - Bielorussia 13
PA - Panama 13
TW - Taiwan 13
AL - Albania 12
KG - Kirghizistan 12
RS - Serbia 12
AM - Armenia 11
BO - Bolivia 11
BH - Bahrain 10
DK - Danimarca 10
LV - Lettonia 10
MD - Moldavia 10
SI - Slovenia 10
SY - Repubblica araba siriana 10
CI - Costa d'Avorio 9
HR - Croazia 9
KW - Kuwait 9
Totale 85.244
Salva come PNG Salva come JPEG
Città #
Singapore 6.591
Wilmington 5.565
Chandler 4.576
Ashburn 2.550
The Dalles 2.234
San Jose 2.043
San Mateo 2.025
Dallas 1.889
Ann Arbor 1.547
Shanghai 1.480
Helsinki 1.397
Council Bluffs 1.266
Dublin 1.121
Milan 1.010
Princeton 1.000
Leawood 943
New York 919
Lawrence 911
Boardman 841
Benin City 804
Ho Chi Minh City 795
Beijing 786
Hong Kong 682
Santa Clara 587
Hanoi 576
Paris 519
Woodbridge 518
Fairfield 516
Los Angeles 516
Rome 359
Toronto 354
Amsterdam 330
São Paulo 314
Phoenix 301
Seattle 269
Buffalo 264
London 233
San Diego 215
Columbus 194
North Bergen 183
Kocaeli 180
Chicago 146
Rio de Janeiro 134
Norwalk 131
Da Nang 122
Brooklyn 120
Atlanta 109
Haiphong 105
Orem 99
Charlotte 96
Houston 95
Belo Horizonte 94
Montreal 94
Brussels 88
Warsaw 86
Philadelphia 83
Tokyo 83
Naples 81
Falkenstein 79
Pune 78
Brasília 76
Falls Church 76
Figino 74
Miami 71
Las Vegas 70
Baghdad 67
Queens 67
Chennai 65
Mexico City 64
Curitiba 63
Tashkent 63
Denver 61
Porto Alegre 61
Redwood City 61
Guayaquil 59
The Bronx 59
San Francisco 58
Munich 57
Boston 56
Johannesburg 56
Moscow 54
Manchester 52
Dhaka 51
Monmouth Junction 50
Campinas 49
Frankfurt am Main 49
Hải Dương 46
Cleveland 44
Biên Hòa 43
Jacksonville 43
Pittsburgh 43
Richmond 43
Washington 43
Pasadena 41
San José 41
Mumbai 40
Salvador 40
Turin 40
Abbiategrasso 39
Cincinnati 39
Totale 53.500
Salva come PNG Salva come JPEG
Nome #
Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer 187
Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis 185
KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL) 179
A Case of Pulmonary Sarcoidosis during First-Line Targeted Therapy with Dabrafenib Plus Trametinib in BRAF V600E-Mutated Metastatic Melanoma 174
An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab 174
Primary refractory and early-relapsed Hodgkin's lymphoma : strategies for therapeutic targeting based on the tumour microenvironment 174
18F-FDG PET and CT scan in the pre-operative evaluation of colorectal liver metastases treated with chemotherapy 168
A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogenic stem call transplantation from a HLA identical sibling 166
18F-FDG pet does not improve contrast enhanced CT scan sensitivity in the evaluation of liver metastases after chemotherapy 163
Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study 161
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 160
A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial 158
Hypofractionation with simultaneous boost in breast cancer patients receiving adjuvant chemotherapy: A prospective evaluation of a case series and review of the literature 156
A PHASE 1 SAFETY STUDY OF ONCOFID-P-B ADMINISTERED FOR 12 CONSECUTIVE WEEKS IN BCG UNRESPONSIVE/INTOLERANT PATIENTS WITH BLADDER CARCINOMA IN SITU (CIS): PRELIMINARY RESULTS 153
Assessment of prognostic factors in patients with metastatic epidural spinal cord compression (MESCC) from solid tumor after surgery plus radiotherapy: a single institution experience 153
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma 152
Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases 149
Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study 149
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 146
A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer 145
A circulating miRNA signature to implement diagnostic imaging analysis in young early-stage breast cancer patients 145
A new human cell line, PDSS-26, from poorly differentiated synovial sarcoma, with unique chromosomal anomalies 144
A. Micrometastasis in sentinel (SLN) and non sentinel lymph nodes of breast cancer: an update including clinico-pathologic impact and survaival 143
Gene methylation in pleural mesothelioma : Correlations with clinico-pathological features and patient’s follow-up 142
Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non-Small-Cell Lung Cancer. 142
Tivantinib for hepatocellular carcinoma 142
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma 142
An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers 141
BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors 141
Role of consolidation RT to bulky lesions of advanced Hodgkin lymphoma: results of FIL HD0801 trial 140
Carbon-11-methionine PET-CT as an imaging biomarker in brain gliomas eligible for surgery 139
Metastasis of hepatocellular carcinoma to the heart: A case report and review of the literature 138
A phase I clinical and pharmacokinetic study evaluating vinflumine in combination with epirubicin as first-line treatment in metastatic breast cancer 138
A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Circulating Tumor DNA 137
Alternating drug combinations in the treatment of advanced Hodgkin's disease. 137
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 137
Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme 137
High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid 135
Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patients’ management: close to clinic 135
A Phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small cell lung cancer. 134
A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies 132
Initial chemotherapy for primary resectable large-cell lymphoma of the stomach 132
Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas 132
A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer 131
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis 131
Biological characteristics and long-term outcomes in node-negative breast cancer 130
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study 130
VINORELBINE (V) IN PEMETREXED-PRETREATED PATIENTS (PTS) WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 130
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer 129
Cardioprotection with nebivolol in patients undergoing anthracyclines: a randomized placebo-controlled trial 128
Biomarkers in Hepatocellular Carcinoma-Letter 128
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 128
Outcome appraisal of patients with limited brain metastases (BMs) from non small cell lung cancer (NSCLC) treated with different local therapeutic strategies: a single institute evaluation. 127
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors 127
Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up 126
Treatment of malignant pleural mesothelioma: current status and future directions 126
Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy 124
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 124
Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy 123
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 122
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised international prognostic scoring system (IPSS-R) 122
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection 121
Survival outcome and prognostic factors after pulmonary metastasectomy in sarcoma patients 121
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach 121
DEXAMETHASONE, GRANISETRON, OR BOTH FOR THE PREVENTION OF NAUSEA AND VOMITING DURING CHEMOTHERAPY FOR CANCER 121
Short schedule of cisplatin and vinorelbine: A dose-finding study in non-small-cell lung cancer 121
COVID-19 and liver cancer clinical trials: not everything is lost 120
COMBINED-MODALITY TREATMENT FOR PRIMARY GASTROINTESTINAL NON-HODGKINS-LYMPHOMA - THE MILAN CANCER INSTITUTE EXPERIENCE 120
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma 120
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC) 119
Early Surgical Experience with Minimally Invasive Percutaneous Approach for Patients with Metastatic Epidural Spinal Cord Compression (MESCC) to Poor Prognoses 119
High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant 119
Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome 119
Clinical relevance of clonal hematopoiesis in persons aged ≥80 years 119
Clinical Effects of Driver Somatic mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With allogeneic Hematopoietic Stem-Cell Transplantation 118
. The level of HER2/neu amplification may have a correlation with some relevant histopathologcal features of early stage breast cancer 118
Superiority of CHOI vs RECIST criteria in evaluating outcome of advanced soft tissue sarcoma (STS) patients treated with sorafenib 117
Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: rationale, background studies, and recent results. 115
Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. 115
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 115
Adjuvant volumetric modulated arc therapy compared to 3D conformal radiation therapy for newly diagnosed soft tissue sarcoma of the extremities: outcome and toxicity evaluation 115
Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives 115
A monocentric retrospective analysis of TILs and AR as hints for prognosis definition in TNBC 115
A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma 114
Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial 114
Tumor-derived PGD2 and NKp30 –B7H6 engagement drives an immunosuppressive ILC2-MDSC axis 114
Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top" 114
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 114
Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: Can it be safely associated with fluorouracil-based chemotherapy? 113
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 113
Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography 113
PHASE II STUDY OF THE COMBINATION OF BEVACIZUMAB PLUS PEMETREXED AND CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 113
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma 112
Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. 112
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 112
Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery 112
Advances in the biology of malignant pleural mesothelioma 112
The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer 112
Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction 111
Percutaneous Vertebral Augmentation in Metastatic Disease: State of the Art 111
Totale 13.242
Salva come PNG Salva come JPEG
Categoria #
all - tutte 562.065
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 562.065
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.470 0 0 0 1.100 86 83 202 732 426 556 1.050 235
2022/202312.810 2.013 413 1.232 1.406 1.154 1.075 32 1.083 2.224 1.120 906 152
2023/20246.764 616 732 1.517 242 195 721 323 368 87 140 696 1.127
2024/202510.261 245 192 54 176 234 1.187 534 1.207 1.458 2.604 1.158 1.212
2025/202629.275 4.175 1.970 1.856 2.948 755 1.187 8.085 1.668 1.676 1.707 1.130 2.118
2026/202711.648 2.707 2.556 4.430 1.955 0 0 0 0 0 0 0 0
Totale 86.152